← Leaderboards
John Kent Werner
Cogentis Therapeutics, Inc.
$2,577,401
Attributed
$2,944,124
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,944,124 · 2
By mechanism
R44$2,210,678 · 1
R43$733,446 · 1
Top collaborators
- Sanjeev Thohan2 shared
Most similar at Cogentis Therapeutics, Inc.
Same institution · by research overlap
- Sanjeev Thohan$366,723
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsCellsNerve DegenerationPeptidesToxic EffectTau ProteinsDrug DevelopmentMouse ModelNeurodegenerative DisordersNovel TherapeuticsPhosphotransferasesPre-ClinicalResponseSmall Business Innovation Research GrantCompanionsDoseExosomeLinkBrainAlzheimer&AposAutopsyNeuronsPreservationBlood
Grant awards (4)
Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis$1,027,314
R44 · FY2022 · NS · contact PI
Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis$1,183,364
R44 · FY2021 · NS · contact PI
Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia$236,325
R43 · FY2020 · AG · contact PI
Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia$497,121
R43 · FY2018 · AG · contact PI